Restricted accessEditorialFirst published online 2024-11
Patient safety,pharmacovigilance and liability through the current vaccine crisis,disaster in pharmaceutical promotion and various global patient safety concerns
TayarJHLopez‐OlivoMASuarez‐AlmazorME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev2012; 11(11): CD008653. DOI: 10.1002/14651858.CD008653.pub2 (accessed 18 October 2024).
3.
Jaspreet Kaur Sidhu and Deepti Chopra. Febuxostat induced Stevens Johnson syndrome: A case report. Int J Risk Saf Med2024, Inpress.
4.
BolcatoVBasileGTronconiLP, et al.Telemedicine in Italy: Healthcare authorization profiles in the modern medico-legal reading. Int J Risk Saf Med. 2024. DOI: 10.3233/JRS-240004.
5.
JablonowskiKHookerB. Adverse outcome detection of childhood administered thimerosal-free HibTITER®. Int J Risk Saf Med2024, Inpress.
6.
KiddeerMBasitAAhmadT, et al.Needle stick injuries and post-exposure prophylaxis practices among healthcare personnel working at tertiary care hospitals in Punjab, Pakistan. Int J Risk Saf Med2024; vol. Pre-press, no. Pre-press: 1–12.
7.
RhodesPIgnatius ParryP. Pharmaceutical product recall and educated hesitancy towards new drugs and novel vaccines. Int J Risk Saf Med2024, Inpress.
